{\rtf1\ansi\ansicpg1252\cocoartf949\cocoasubrtf430
{\fonttbl\f0\froman\fcharset0 TimesNewRomanPSMT;\f1\fswiss\fcharset0 ArialMT;}
{\margl1800\margr1600\margt500\margbl1440}
{\pard\sa900\fs50\f0\i Media Release\par}
{\pard\f0\li0\ri0\sa360\sl360\fs22 Basel, 27 June 2005\line \line {\b Tarceva 
receives positive opinion in EU for the treatment of patients with lung cancer} \line \line Roche 
announced today that its innovative, oral cancer medicine Tarceva (erlotinib) has received a positive 
recommendation from the European Committee for Medicinal Products for Human Use (CHMP) for the treatment 
of non-small cell lung cancer, the most common form of lung cancer. \line \line \u8220?This 
decision is proof of the impressive survival benefit that Tarceva offers patients with late stage lung 
cancer,\u8221? said William M. Burns, CEO Division Roche Pharma. \u8220?This brings new hope to lung cancer patients 
who have currently very limited treatment options.\u8221? \line \line Tarceva is the first 
and only EGFR-targeted treatment to have shown a significant survival benefit in patients with non-small 
cell lung cancer (NSCLC) and offers new hope to the 370, 000 people suffering with lung cancer each 
year in Europe.{\super {\pard\f0\li0\ri0\sa360\sl360\fs18 1\par}}  EGFR is a key component 
of the human epidermal growth factor receptor pathway, which plays a role in the formation and growth 
of numerous cancers.\line \line The CHMP has recommended that Tarceva is indicated 
for the treatment of patients with locally advanced or metastatic non small cell lung cancer after failure 
of at least one prior chemotherapy regimen. When prescribing Tarceva, factors associated with prolonged 
survival should be taken into account. No survival benefit or other clinically relevant effects of the 
treatment have been demonstrated in patients with EGFR-negative tumours. The CHMP recommendation is 
based on data from a pivotal phase III{\super {\pard\f0\li0\ri0\sa360\sl360\fs18 2\par}}  
study which compared Tarceva to placebo for the treatment of patients with advanced NSCLC, following 
failure of first or second-line chemotherapy. Patients receiving Tarceva lived significantly longer 
than those in the placebo arm. There was also a significant increase in both the length of time before 
patients\u8217? disease symptoms deteriorated and the time when patients were stable and there was no progression 
of their cancer. It was also observed that one out of three patients on Tarceva was alive at one year 
as opposed to only one of five in the placebo group. There is no specific recommendation for EGFR IHC 
(immunohistochemistry) testing. \line \line Lung cancer is the most common cancer 
worldwide{\super {\pard\f0\li0\ri0\sa360\sl360\fs18 3\par}}  with 1.2 million new cases 
annually with someone, somewhere dying of the disease every 30 seconds.{\super {\pard\f0\li0\ri0\sa360\sl360\fs18 4\par}}  
NSCLC accounts for almost 80 percent of all lung cancer cases and there are few treatment options available. 
\line \line {\b About Tarceva} \line Tarceva is an investigational 
small molecule that targets the human epidermal growth factor receptor (HER1) pathway. HER1, also known 
as EGFR, is a key component of this signalling pathway, which plays a role in the formation and growth 
of numerous cancers. Tarceva blocks tumour cell growth by inhibiting the tyrosine kinase activity of 
the HER1 signalling pathway inside the cell. \line \line Similarly to the significant 
survival benefit in NSCLC, Tarceva has also shown survival benefit in a phase III study in locally advanced 
or metastatic pancreatic cancer patients. The study met its primary endpoint of improving overall survival. 
\line \line Tarceva is currently being evaluated in an extensive clinical development 
programme by a global alliance among OSI Pharmaceuticals, Genentech, and Roche. Chugai is pursuing its 
development and regulatory approval for the Japanese market. In the United States, Tarceva is marketed 
by Genentech.\line \line {\b About Roche} \line Headquartered 
in Basel, Switzerland, Roche is one of the world\u8217?s leading research-focused healthcare groups in the 
fields of pharmaceuticals and diagnostics. As a supplier of innovative products and services for the 
early detection, prevention, diagnosis and treatment of disease, the Group contributes on a broad range 
of fronts to improving people\u8217?s health and quality of life. Roche is a world leader in diagnostics, 
the leading supplier of medicines for cancer and transplantation and a market leader in virology. In 
2004 sales by the Pharmaceuticals Division totalled 21.7 billion Swiss francs, while the Diagnostics 
Division posted sales of 7.8 billion Swiss francs. Roche employs roughly 65,000 people in 150 countries 
and has R&D agreements and strategic alliances with numerous partners, including majority ownership 
interests in Genentech and Chugai. Additional information about the Roche Group is available on the 
Internet (www.roche.com (http://www.roche.com)).\line \line {\pard\f0\li0\ri0\sa360\sl360\fs18 All trademarks 
used or mentioned in this release are protected by law.\par}\line \line  
\line {\pard\f0\li0\ri0\sa360\sl360\fs18 References:\line 1. J. Ferlay, F. Bray, P. Pisani and D.M. 
Parkin. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0. IARC CancerBase 
No. 5. Lyon, IARCPress, 2001.\line 2. Shepherd, F. A randomized placebo-controlled trial of 
erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line 
or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC), (Abstract 
#7022), ASCO 2004. \line 3. World Health Organisation, World Cancer Report, 2003. \line 4. 
www.lungcancercoalition.org/cancer_facts.html.\par}\line \line {\b Additional 
information} \line - Genentech (http://www.gene.com): www.gene.com\line - OSI 
Pharmaceuticals (http://www.osip.com): www.osip.com\line - Cancer (http://www.health-kiosk.ch/start_krebs): www.health-kiosk.ch\line - 
Roche in Oncology (http://www.roche.com/mboncology-e.pdf)\par}
{\pard \par}
{\pard\sb180\f1\fs22 {\b F. Hoffmann-La Roche Ltd}\line 4070 Basel\line Switzerland \par}
{\pard\sb180\f1\fs22 Corporate Communications\line Roche Group Media Relations \par}
{\pard\sb180\f1\fs22 Tel. +41 61 688 88 88\line Fax +41 61 688 27 75\line www.roche.com \par}
}